Literature DB >> 28475311

Targeting and Internalization of Liposomes by Bladder Tumor Cells Using a Fibronectin Attachment Protein-Derived Peptide-Lipopolymer Conjugate.

Young Lee1, Erin Kischuk1, Scott Crist1, Timothy L Ratliff1, David H Thompson1.   

Abstract

A synthetic peptidolipopolymer conjugate, incorporated into liposomes to promote specific binding to the fibronectin (FBN) matrix surrounding bladder tumor cells and promote cellular internalization of FBN-integrin complexes, is reported. The peptide promotes association with MB49 mouse model bladder tumor cells in a sequence-specific and concentration-dependent manner, with the maximum cell association occurring at 2 mol % RWFV-PEG2000-DSPE. Double PEGylation of the liposome membrane (i.e., 4 mol % mPEG1000-DSPE + 2 mol % RWFV-PEG2000-DSPE) enhanced binding by >1.6-fold, by improving ligand presentation on the liposome surface. The sequence specificity of the peptide-lipopolymer construct was confirmed by comparing liposomes containing RWFV-PEG2000-DSPE with scrambled and nonpeptidic lipopolymer liposomal formulations. MB49 tumor-bearing mice showed greater mean radiance values for FAP peptide-targeted liposomes in tumor-associated regions of interest than for nontargeted and scrambled peptide liposome formulations. These findings suggest that peptide-modified liposomes may be an attractive vehicle for targeted delivery to bladder tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28475311      PMCID: PMC6502482          DOI: 10.1021/acs.bioconjchem.7b00153

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  41 in total

1.  Ligand-targeted liposomes.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-02-02       Impact factor: 15.470

2.  Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.

Authors:  J L Au; R A Badalament; M G Wientjes; D C Young; J A Warner; P L Venema; D L Pollifrone; J D Harbrecht; J L Chin; S P Lerner; B J Miles
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

3.  Differential detection of phospholipid fluidity, order, and spacing by fluorescence spectroscopy of bis-pyrene, prodan, nystatin, and merocyanine 540.

Authors:  Heather A Wilson-Ashworth; Quinn Bahm; Joshua Erickson; Aaron Shinkle; Mai P Vu; Dixon Woodbury; John D Bell
Journal:  Biophys J       Date:  2006-09-15       Impact factor: 4.033

4.  Fibronectin attachment protein is necessary for efficient attachment and invasion of epithelial cells by Mycobacterium avium subsp. paratuberculosis.

Authors:  T E Secott; T L Lin; C C Wu
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

5.  Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity.

Authors:  W Zhao; J S Schorey; M Bong-Mastek; J Ritchey; E J Brown; T L Ratliff
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

6.  Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells.

Authors:  Annelies S L Derycke; Appolinary Kamuhabwa; Antoon Gijsens; Tania Roskams; Dirk De Vos; Ahmad Kasran; Jörg Huwyler; Ludwig Missiaen; Peter A M de Witte
Journal:  J Natl Cancer Inst       Date:  2004-11-03       Impact factor: 13.506

Review 7.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

8.  Ligand-receptor interactions between surfaces: the role of binary polymer spacers.

Authors:  Gabriel S Longo; David H Thompson; I Szleifer
Journal:  Langmuir       Date:  2008-08-13       Impact factor: 3.882

9.  Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator of fibronectin turnover.

Authors:  Feng Shi; Jane Sottile
Journal:  J Cell Sci       Date:  2008-06-24       Impact factor: 5.285

Review 10.  Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

Authors:  Sven Brandau; Henrik Suttmann
Journal:  Biomed Pharmacother       Date:  2007-06-12       Impact factor: 6.529

View more
  5 in total

1.  Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer.

Authors:  Fabrizio Di Maida; Cristina Scalici Gesolfo; Riccardo Tellini; Andrea Mari; Chiara Sanfilippo; Luca Lambertini; Antonio Andrea Grosso; Marco Carini; Andrea Minervini; Vincenzo Serretta
Journal:  Ther Adv Urol       Date:  2021-02-27

2.  Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.

Authors:  Kai-Wen Ho; I-J U Chen; Yi-An Cheng; Tzu-Yi Liao; En-Shuo Liu; Huei-Jen Chen; Yun-Chi Lu; Yu-Cheng Su; Steve R Roffler; Bo-Cheng Huang; Hui-Ju Liu; Ming-Yii Huang; Chiao-Yun Chen; Tian-Lu Cheng
Journal:  J Nanobiotechnology       Date:  2021-01-09       Impact factor: 10.435

Review 3.  Advances in Research on Bladder Cancer Targeting Peptides: a Review.

Authors:  Bin Zheng; Pu Zhang; Heng Wang; Jinxue Wang; Zheng Hong Liu; DaHong Zhang
Journal:  Cell Biochem Biophys       Date:  2021-09-01       Impact factor: 2.194

4.  Research Progress of Nanomaterial Mechanics for Targeted Treatment of Muscle Strains in Sports Rehabilitation Training.

Authors:  Fengping Huang
Journal:  Appl Bionics Biomech       Date:  2022-04-14       Impact factor: 1.664

5.  Development And In Vitro Characterization Of Bladder Tumor Cell Targeted Lipid-Coated Polyplex For Dual Delivery Of Plasmids And Small Molecules.

Authors:  Shayak Samaddar; Joshua Mazur; Devin Boehm; David H Thompson
Journal:  Int J Nanomedicine       Date:  2019-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.